Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04633811 · ClinicalTrials.gov registry record · NA
Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers
A NA study of Kidney Stone, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04633811: Active NA study of Kidney Stone, sponsored by University of Alabama at Birmingham.
NCT04633811 is a NA study of Kidney Stone that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 14 participants, below the 192-participant average among 28 other Kidney Stone trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04633811, a NA study of Kidney Stone, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis and dietary oxalate absorption to the urinary oxalate pool in obese calcium oxalate stone formers.
Primary Outcome
Subjects will ingest a controlled diet low in oxalate and collect 2 x 24-hour urines before and after the Optifast VLCD Program. The utilization of a low oxalate diet allows assessment of the change in contribution of endogenous oxalate synthesis to the urinary oxalate pool.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Low Oxalate Diet before Weight Loss
- DIETARY_SUPPLEMENT Oral load of oxalate and sucralose before Weight Loss
- DIETARY_SUPPLEMENT Optifast VLCD Program
- DIETARY_SUPPLEMENT Optifast VLCD Transition Phase
- DIETARY_SUPPLEMENT Low Oxalate Diet after Weight Loss
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-12-03 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT04633811 still lists
NCT04633811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 192-participant average among 28 other Kidney Stone trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Kidney Stone appearing as the primary indexed condition, and to 5 interventions - of which Low Oxalate Diet before Weight Loss is the first listed.
NCT04633811 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04633811 about?
NCT04633811 is a clinical study titled "Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers". This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis and dietary oxalate absorption to the urinary oxalate pool in obese calcium oxalate stone formers.
What is the current status of trial NCT04633811?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 14 participants. The study started on 2021-12-03. Estimated completion is 2026-12-31.
What conditions does trial NCT04633811 study?
This clinical trial studies the following conditions: Kidney Stone.
What interventions are being tested in trial NCT04633811?
The interventions under investigation include: Low Oxalate Diet before Weight Loss (DIETARY_SUPPLEMENT), Oral load of oxalate and sucralose before Weight Loss (DIETARY_SUPPLEMENT), Optifast VLCD Program (DIETARY_SUPPLEMENT), Optifast VLCD Transition Phase (DIETARY_SUPPLEMENT), Low Oxalate Diet after Weight Loss (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04633811?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04633811 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Stone
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04633811's enrollment target sits among peer trials
14 28th of 28 higher than 1 of 28 other Kidney Stone trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Stone trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
Gut Oxalate Absorption in Calcium Oxalate Stone Disease
RECRUITING · NA
-
High Powered Stone Dusting vs. Fragmentation and Basketing at Time of Ureteroscopy
RECRUITING · NA
-
Access Sheath and Stent Trial
RECRUITING · NA
-
GI Oxalate Absorption
RECRUITING · NA
-
Evaluation of the LithoVue Elite Ureteroscope With Intra-Renal Pressure Monitoring Technology: Examination of Surgeon Behavior and Post-operative Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy